PHOENIX, April 26, 2018 (GLOBE NEWSWIRE) -- William Hartman, CEO of Premier Biomedical Inc. (OTCBB:BIEI) ("the Company") joined Everett Jolly on Uptick Newswire’s “Stock Day” podcast to discuss recent company developments.
Premier Biomedical consists of two groups: The Biologics Group deals fundamentally with the treatment of disease, both extra-corporeally and via immunotherapy, while the second group, Pain Relief Meds.Com, has developed hemp oil CBD topical pain relief products (www.painreliefmeds.com). According to Hartman, the pain relief team has developed stronger formulas for their oil-based roll-ons, sprays, and ointments that contain one of the highest levels of CBD in the industry. These will be released at the Sorinex Summer Strong Event on May 18-20, 2018.
Hartman also addressed the concern over recent news about the company’s upcoming reverse split. Developments within the regulatory agencies are forcing sub-penny stocks to be increasingly difficult to be sold. “We’ve thought about it, and we’ve researched it through experts who have told us that a reverse split could be a great thing. There are many people that are interested in our product and our stock, but they won’t buy the stock because of its sub-penny status.” The goal of the split is to allow Premier Biomedical increased margin between authorized share limits and outstanding shares, and to put the company in a position to permit upward movement of their stock price. As a result of the improved stock price status, potential joint venture partners and major investors are in a position to view joint ventures, partnerships, and investments in a more favorable light. The company's goal is to achieve the status of being an independent, self-financed organization in 2018, and these recent actions will contribute to that goal.
“It’s been a long, hard journey,” Hartman said, “but things are really looking up for us with all of our new products, as well as our exciting new intellectual properties."
For more details on the company, click the link below to hear the rest of the interview. You will also hear more about the company’s international expansion goals, participation in the Sorinex Summer Strong event in May, and efforts to combat opioid addiction.
About Premier Biomedical
Premier Biomedical, Inc. has acquired exclusive licenses for patent-pending medications/medical procedures to develop cures for a significant number of the most debilitating and often fatal illnesses affecting mankind: Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI), Multiple Sclerosis (MS), Clinical Depression, Alzheimer’s Disease, Blood Sepsis, Atherosclerosis and Cancer. We have developed an aggressive timetable to advance the development of these breakthrough technologies though laboratory, hospital, and clinical trials. We have initiated the development of potential patient trial application lists. We have a management team with extensive experience and contacts in the medical/pharmaceutical fields as well as demonstrated track record of launching new business ventures in a competitive environment. Our extensive contacts in the medical/pharmaceutical industries will ensure that new developments will achieve maximum visibility and exposure to the market. Transparency and accountability will continue to be ensured via regular issuance of technical progress reports, financials, and investor relations reports to maintain investor enthusiasm.
Premier Biomedical, Inc., a Nevada corporation, is a fully reporting issuer under the Securities Exchange Act of 1934, listed under “BIEI” on the OTC-BB Index.
Safe Harbor Statement
Certain statements contained herein are “forward-looking statements,” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements and assumptions made in this news release constitute forward-looking statements; the company makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, and other estimates made by management. Actual results could differ from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
About Uptick Newswire
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire and has recently launched the Video Interview Studio located in Phoenix, Arizona.
Contact Information:
William A. Hartman
President & CEO
Premier Biomedical Inc.
(724) 633-7033
w.hartman@premierbiomedical.com
www.premierbiomedical.com